Mon, Mar 2, 2015, 11:26 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

NPS Pharmaceuticals, Inc. Message Board

  • abusaid22220 abusaid22220 May 6, 2013 10:36 AM Flag

    Short term prognostication/wild #$%$ guess

    I think it will climb over $14 between now and Thursday morning. After earnings, I have no idea how people will react in the short term. Someone here said that they would not give any revised numbers on Gattex sales during this earnings announcement/conference call. We're so early in the Gattex ramp up, I don't expect mind blowing numbers, and if true, that could cause a short term sell off. But then, Netpara sales could be moving the boat faster than expected, so the opposite could happen. In any event, NPSP still has quite a way to go. This is definitely a keeper.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Let's just follow the last quarter ER conference call, shall we? The CEO said no meaningful revenues until Q2, and more ramp up in Q3 and Q4. So that means that Q1 will likely have higher expenses, ramping up, and lower revenues, as he said. Given the approval process for insurance coverage, I don't expect some big surprise in patient count. Which means a dumass sell off of 1-3 dollars on earnings. i have already made 20K on this stock, so I sold 2/3 today, and depending on stock performance between now and earnings may sell the rest. Longer term this is at least a $20 stock, if not more.

    • Natpara sales? What are you talking about?

    • redivey@gmail.com redivey May 6, 2013 2:12 PM Flag

      this is going up to $18 this year, with 3 drugs in the sack and good management plus happy employees.

 
NPSP
45.970.00(0.00%)Feb 20 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.